See the DrugPatentWatch profile for Adefovir
What is adefovir dipivoxil, and what market does it serve?
Adefovir dipivoxil is an oral prodrug of adefovir, used as an antiviral medicine. It has been marketed for chronic viral infections, most notably chronic hepatitis B (HBV), where it helps suppress viral replication [1].
How big is the adefovir dipivoxil market, and what drives demand?
Demand is mainly driven by the number of patients treated for chronic HBV and by prescribing practices that shift based on guideline preferences, availability of alternatives, and long-term treatment needs [1]. In many markets, newer HBV antivirals have affected how much patients remain on older therapies over time.
Which competitors and alternatives affect adefovir dipivoxil sales?
In chronic HBV, newer antiviral options tend to compete with older agents because of differences in potency and resistance profiles. This competitive pressure can reduce market growth even when overall HBV treatment remains steady [1].
Is the adefovir dipivoxil market growing or shrinking?
The market’s direction typically depends on two opposing forces: ongoing HBV diagnosis and treatment versus switching to more preferred newer antivirals and changes in guideline recommendations. For older HBV drugs, many markets see declining or slower growth as prescribers move to alternatives [1].
Are there regulatory or access factors that impact the market?
Market access depends on national regulatory status, pricing, reimbursement decisions, and whether products are available as branded drugs or generics. Those factors can materially change market size and sales distribution by country [1].
How do generics influence the adefovir dipivoxil market?
Where generic versions are available, competition usually increases and branded revenues often decline. Generic uptake can keep patient access stable even as brand-market value shrinks [1].
Where can you find reliable market data?
To get an accurate market-size figure (e.g., by region, revenue, and forecast), you typically need paid market-research datasets or regulatory/IMS-style sales reporting. Public sources may describe usage and approvals but usually do not provide full revenue estimates without specialized databases [1].
If you tell me which geography you care about (global, US, EU, India, etc.) and whether you want “market size in revenue” or “number of treated patients,” I can narrow the answer to the most relevant interpretation of “market.”
Sources:
[1] https://en.wikipedia.org/wiki/Adefovir_dipivoxil